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Figure 1 -Ring sideroblasts in marrow smears.
The diagnostic criteria are: the presence of anemia with erythroid dysplasia with or without multiple lineage dysplasia, >15% of RS, <1% of blasts in the peripheral blood, and <5% in the bone marrow, persistent thrombocytosis with platelets ≥450.000 L, the SF3B1 mutation (or in its absence, no recent use of cytotoxic or growth factor therapy); none of the following rearrangements: BCR-ABL1; PDFGRA, PDFGRB, FGFR1, PMC1-JAK2, t(3;3)(q21.3;q26.2), inv(3)(q21.3q26.2), del(5q), and; no history of myeloproliferative neoplasm, myelodysplastic syndrome (except MDS-RS), or other MDS/MPN. 1 From the clinical point of view at diagnosis, many cases seem like ET with a trend to an enlarged mean corpuscular volume (MCV) and near normal hemoglobin values. The guiding principle for the diagnosis is the iron staining by Prussian blue (Perl's reaction). Should this test not be performed, the cases would remain misdiagnosed as ET.
The RSs are erythroid precursors containing iron-loaded mitochondria (ferritin) surrounding more then 1/3 of the nucleus ( Figure 1 ). In addition to the clonal conditions associated with the RS, such as MDS, ET and primary myelofibrosis, the RS may appear due to exposure to alcohol, some drugs (isoniazid, chloramphenicol, linezolid and penicillamine), lead and zinc intoxication, copper or pyridoxine deficiency, and as inherited conditions, some X-linked. However, regardless of the cause, RS identifies ineffective erythropoiesis and mitochondrial iron overload. The mitochondrial ferritin is not detectable in normal erythropoiesis. The molecular pathogenesis is that the SFB3B1 mutation could alter the ABCB7 gene expression dysregulating mitochondrial iron homeostasis, consequently forming the ring sideroblasts. 6, 7 The SF3B1 (splicing factor 3B subunit 1) gene is located on the chromosome 2q33.1, is involved in the spliceosome, being K700E the most frequent (>50%) mutation. When the SF3B1mut is detected, the RARS with reacting thrombocytosis is ruled out. The SF3B1mutation dysregulates mitochondrial iron homeostasis, resulting in the formation of the RS. It is thought that the SF3B1 haploinsufficiency correlates with the development of the RS, supported by the fact that its pharmacological inhibitor, meayamycin, induces the RS in healthy in vitro BM cells of sf3b1-heterozygous-knock-out mice. 6 Considering the predictors of survival, Patnaik et al. (2016), 7 developed a prognostic model based on the mutational profile ( Table 1) .
As for therapy, the MDS/MPN-RS-T patients are frequently treated with erythropoiesis stimulating agents (if the serum levels of EPO are <500 mU/mL) or transfusions for anemia; antiplatelet agents (ex. low dose aspirine) for reduction of the risk for arterial thrombosis, and; cytoreductive therapy (ex. Hydroxyurea, Interferon) for those cases with increased risk for thrombosis. 4, 5, 7 In the case of marked thrombocytosis (≥1000 × 10 9 /L), or any evidence of bleeding, an investigation for acquired von Willebrand's disease (VW) should be conducted (antigen, ristocetin cofactor activity and VW's multimeric pattern) before starting aspirin. Treatment of the underlying medical condition may result in remission, but more than one therapeutic approach is often necessary to treat acute bleeding and prophylaxis during invasive procedures and include desmopressin, VWF-containing concentrates, intravenous immunoglobulin, plasmapheresis, or recombinant factor VIIa. 8 In summary, the precise diagnostic work-up associated with the mutational profile is important to distinguish this entity from the ET and MDS-RS.
